ArticleInterdisciplinary cardiovascular and thoracic surgery2024
Surgical indications for pleurectomy/decortication in pleural mesothelioma based on the newly revised 9th edition of the tumour-node-metastasis classification.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Diagnostic Challenges in Pleural Mesothelioma.Cancers · 2026Review
- Feasibility of multimodality treatment, including pleurectomy decortication, in carefully selected patients with sarcomatoid mesothelioma.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesThe MARS2 trial questioned the efficacy of curative intent surgery for pleural mesothelioma (PM), while real-world clinical data from Japan suggest a favourable prognosis in surgical cases, indicating survival benefits in selected patients. The newly revised 9th edition of the tumour-node-metastasis (TNM) classification introduces a novel indicator based on pleural thickness.
methodsWe conducted a retrospective evaluation of patients with PM who underwent pleurectomy/decortication between 2012 and 2022. Patient characteristics, complications and treatment outcomes were assessed. Additionally, outcomes were analysed based on the 9th edition of the TNM classification.
resultsA total of 62 patients were included in the analysis. The median overall survival (OS) was 37.3 months, with a median relapse-free survival (RFS) of 15.5 months. Patients with the epithelioid subtype (OS: 61.6 months; RFS: 26.0 months) and pStage IA (OS: not reached; RFS: 69.1 months) had significantly better outcomes. The 9th edition of the TNM classification showed a stronger prognostic correlation than the 8th edition, with a median OS of 77.0, 31.9, 20.4 and 25.3 months for stages I, II, IIIA and IIIB (P = 0.0016) and median RFS of 34.3, 12.3, 13.7 and 6.9 months for stages I, II, IIIA and IIIB (P = 0.013), respectively.
conclusionsSurgical intervention remains crucial in the treatment of PM, particularly for patients with epithelioid histology and early stages of the disease. This study evaluates surgical indications for PM using the newly revised 9th edition of the TNM classification, indicating that it enhances the precision of surgical candidate selection and potentially improves patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.